Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Sponsor Directory

Janssen Research & Development, LLC clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
703
Shown on this page
12
Current sort
Recently updated
Sponsor scope
Janssen Research & Development, LLC
Additional filters apply within this sponsor.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within Janssen Research & Development, LLC. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 529–540 of 703 matching trials for sponsor Janssen Research & Development, LLC.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

NCT02841150
View directory record Official record
Conditions
Healthy
Interventions
IMBRUVICA (Treatment A), Ibrutinib (Treatment B)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Nov 5, 2026, 3:22 PM EST
Terminated Phase 1 Interventional

A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer

NCT02671955
View directory record Official record
Conditions
Advanced Cancer
Interventions
JNJ-61610588
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
New York, New York • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Nov 5, 2026, 3:22 PM EST
Completed Phase 3 Interventional Results available

A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)

NCT01606761
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Sirukumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
81
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Nov 5, 2026, 3:22 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

NCT01024036
View directory record Official record
Conditions
Multicentric Castleman's Disease
Interventions
Siltuximab, Placebo, Best Supportive Care (BSC)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Nov 5, 2026, 3:22 PM EST
Completed Phase 3 Interventional Results available

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

NCT00338286
View directory record Official record
Conditions
Breast Cancer, Neoplasm Metastasis
Interventions
Standard supportive care (packed RBC transfusion), epoetin alfa + packed RBC transfusion
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
2,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
14
States / cities
Anaheim, California • Gainesville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Nov 5, 2026, 3:22 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants

NCT02933580
View directory record Official record
Conditions
Healthy
Interventions
JNJ-56136379, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2018 · Synced Nov 5, 2026, 3:22 PM EST
Completed Phase 3 Interventional Results available

A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)

NCT01604343
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Sirukumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
48
States / cities
Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Nov 5, 2026, 3:22 PM EST
Completed Phase 1 Interventional

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT02009488
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
San Diego, La Jolla, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Nov 5, 2026, 3:22 PM EST
Completed Phase 2 Interventional Results available

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

NCT02293395
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Acetylsalicylic acid, Rivaroxaban, Clopidogrel, Ticagrelor
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
3,037 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
49
States / cities
Alexander City, Alabama • Banning, California • Sylmar, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Nov 5, 2026, 3:22 PM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)

NCT03059303
View directory record Official record
Conditions
Healthy
Interventions
Simeprevir 75 mg, Odalasvir 25 mg, Odalasvir 12.5 mg, Odalasvir 75 mg, AL-335 800 mg, Lansoprazole 30 mg, Omeprazole 20 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Nov 5, 2026, 3:22 PM EST
Completed Phase 3 Interventional Results available

A Study of Golimumab in Participants With Active Psoriatic Arthritis

NCT02181673
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Placebo, Golimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Glendale, Arizona • Mesa, Arizona • Huntington Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Nov 5, 2026, 3:22 PM EST
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335

NCT02894905
View directory record Official record
Conditions
Renal Insufficiency
Interventions
AL-335
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Nov 5, 2026, 3:22 PM EST

About this Janssen Research & Development, LLC sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where Janssen Research & Development, LLC is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Janssen Research & Development, LLC trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, or open the full search for Janssen Research & Development, LLC.